Can an MRI tell if a brain tumour is benign or malignant?

An MRI gives a strong, educated estimate — but not a certain answer. Radiologists look at how a tumour takes up contrast, how sharp its edges are, how much swelling surrounds it, and whether it crosses the midline. A small, well-defined tumour attached to the brain lining often looks benign (a likely meningioma). An irregular tumour with a dying centre and heavy swelling looks more aggressive. Advanced sequences — perfusion MRI and MR spectroscopy — add useful clues about blood flow and chemistry. Even so, imaging can be wrong in both directions. The only way to confirm benign vs malignant is to examine tumour tissue under a microscope after a biopsy or surgery.

What does it mean if my scan report says the tumour is "likely benign"?

"Likely benign" means the imaging features fit a slow-growing, non-cancerous tumour — but the radiologist cannot be 100% sure from pictures alone. It is a probability, not a diagnosis. Many such tumours (small meningiomas, pituitary adenomas, acoustic neuromas) are watched with repeat MRI over months to confirm they are stable. If a tumour is causing symptoms, growing, or sitting in a risky spot, your team may still recommend a biopsy or surgery to be certain. Bring the report to a neuro-oncology consultation so the words are explained in the context of your symptoms and your specific scan, not in isolation.

Why do doctors still need a biopsy if the MRI already shows the tumour?

An MRI shows the tumour's shape, size, and location — but it cannot see the individual cells or read the tumour's genes. Only a biopsy lets a pathologist confirm the exact type and assign a WHO grade (1 to 4). Critically, modern brain-tumour diagnosis depends on molecular markers — IDH mutation, MGMT methylation, 1p/19q status — which can only be measured on actual tissue. These markers change the treatment plan and the outlook, and two tumours that look identical on MRI can behave very differently once tested. A stereotactic brain biopsy can sample deep tumours through a tiny opening when full surgery is too risky.

Does a benign brain tumour need treatment?

Sometimes yes, sometimes no. "Benign" means the tumour is not cancer and will not spread to other organs — but a benign tumour in a confined space like the skull can still press on vital structures and cause real symptoms. Small, symptom-free benign tumours are often safely monitored with regular MRI ("watch-and-wait"). Treatment is advised when a benign tumour grows, causes seizures, weakness, vision or hearing loss, or sits where pressure is dangerous. Options include surgery (coordinated with our accredited neurosurgical partners) or stereotactic radiosurgery. The decision balances the tumour's behaviour against the risks of intervention — which is exactly what a multidisciplinary tumour board weighs for every patient.

How accurate is a scan at telling cancerous from non-cancerous tumours?

A skilled neuroradiologist using a good-quality MRI with contrast is right most of the time about whether a tumour is likely benign or malignant — but "most of the time" is not the same as certain. Some malignant tumours look deceptively well-behaved early on, and some benign tumours can mimic aggressive features. Advanced techniques (perfusion, spectroscopy, sometimes PET) narrow the gap. This is precisely why guidelines from NCCN and EANO treat imaging as the first step, not the final word. If a tumour's nature affects your treatment, tissue confirmation through biopsy or surgery is the standard of care before major decisions are made.

Can a scan tell which type of brain tumour I have?

Often the scan suggests the most likely type by location and appearance — a tumour on the brain's lining suggests a meningioma; one on the hearing nerve suggests an acoustic neuroma; an irregular mass deep in the brain raises concern for a glioma. But these are pattern-based guesses. The definitive type and grade come from pathology and molecular testing on the tissue. At CION, the MRI, the biopsy result, and the molecular markers are reviewed together by the tumour board so the diagnosis and plan are based on the full picture, not a single image.